Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
41. |
ECCT/13/08/06 | Management of myocardial injury After NoncArdiac surgGEry (MANAGE) Trial |
Principal Investigator(s) 1. GERALD OCHIENG\' YONGA 2. LEONARD MZEE NGUNGA Site(s) in Kenya Aga Khan University Hospital, Nairobi |
30-11-2012 |
View |
42. |
ECCT/12/10/01 | REMEMBER STUDY Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens |
Principal Investigator(s) 1. Lucy N/A Koech Site(s) in Kenya 1. KEMRI/WRP Kericho (Kericho county) 2. AMPATH Moi University Eldoret (Kericho county) |
05-12-2012 |
View |
43. |
ECCT/08/27/12 | MAL 55: A phase III, double blind (observer-blind), randomised, controlled multicenter study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease caused by P. falciparum infection. Protocol No. 110021 - MAL 55 STUDY A phase III, double blind (observer-blind), randomised, controlled multicenter study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease caused by P. falciparum infection, across diverse malaria transmission settings in Africa” |
Principal Investigator(s) 1. Dr. Mary Hamel 2. Dr. Patricia Njuguna 3. Dr. Walter Otieno Site(s) in Kenya 1. KEMRI - CDC RESEARCH INSTITUTION CENTRE, KISUMU (Kisumu county) 2. KEMRI-WELLCOME TRUST RESEARCH CENTER, KILIFI SITE (Kilifi county) 3. KEMRI-WALTERREED, RESEARCH CENTRE, KOMBEWA SITE (Kisumu county) |
07-12-2012 |
View |
44. |
ECCT/13/01/01 | An Open Label Randomized Controlled Phase IIb Trial to Determine the Safety of Oral Fluconazole in Combination with Flucytosine as Compared to Fluconazole Alone |
Principal Investigator(s) 1. Ana-Claire Meyer 2. Judith Kwasa 3. Mark Jacobson Site(s) in Kenya 1. Family AIDS Care and Education Services, Lumumba Health Center (Kisumu county) 2. Family AIDS Care and Education Services, Suba District Hospital (Homa Bay county) |
05-01-2013 |
View |
45. |
ECCT/12/12/01 | A pilot study to optimise controlled human malaria infections in humans with varying degrees of prior exposure to malaria using P. falciparum sporozoites administered by needle and syringe |
Principal Investigator(s) 1. Bernhards Ogutu 2. Kevin Marsh Site(s) in Kenya Kenya Medical Research Institute, Centre for Clinical Research, Nairobi |
18-01-2013 |
View |
46. |
ECCT/13/10/03 | The Impact of Supplementation with Iron and Vitamin B12 Singly and In Combination on Nutritional Status and Morbidity Among Primary School Children. |
Principal Investigator(s) 1. Priscilla Monyangi Dr. Nyakundi Site(s) in Kenya Kilifi County, Ganze District. |
02-02-2013 |
View |
47. |
ECCT/10/09/05 | A5225/ HiFLAC A Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis A Multicenter Trial of the AIDS Clinical Trials Group (ACTG) |
Principal Investigator(s) 1. Deborah Chepngeno langat Site(s) in Kenya 1. |
08-02-2013 |
View |
48. |
ECCT/13/03/01 | Assessing the acceptability of a progesterone vaginal ring (PVR) as a new contraceptive option in sub-Saharan Africa |
Principal Investigator(s) 1. Obare Francis Site(s) in Kenya 1. Ngoliba Health Centre (Kiambu county) 2. Kirwara Sub-district Hospital (Kiambu county) 3. Igegania Sub-district Hospital (Kiambu county) 4. Makadara Health Centre (Nairobi City county) 5. Thika Level 5 (Kiambu county) 6. Ruiru Sub-district Hospital (Kiambu county) |
13-02-2013 |
View |
49. |
ECCT/11/12/04 | PENNVAX-G DNA/MVA HIV Vaccine Phase 1 trial A Phase I Study of the Safety and Immunogenicity of PENNVAX™-G DNA (Env & Gag) Administered by Intramuscular Biojector® 2000 or by CELLECTRA® Intramuscular Electroporation Device Followed by MVACMDR (HIV-1 CM235 env/ CM240 gag/pol) Boost in Healthy, HIV Uninfected Adults |
Principal Investigator(s) 1. FREDRICK KIPYEGO SAWE Site(s) in Kenya KEMRI/Walter Reed Project-Kericho |
15-02-2013 |
View |
50. |
ECCT/13/04/02 | XANTUS EMEA-LA. Xarelto® on prevention of stroke and non-central nervous system systemic embolism in patients with non-valvular atrial fibrillation in Eastern EU, Middle East, Africa (EMEA) and Latin America (LATAM): A non-interventional study |
Principal Investigator(s) 1. Dr Charles Muthui Kariuki Site(s) in Kenya Nairobi Cardiovascular Clinic |
06-03-2013 |
View |